Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

Summary

The primary objective of this study is to evaluate the safety and tolerability of AMG 330, administered in combination with pembrolizumab, in participants with relapsed or refractory acute myeloid leukemia (R/R AML).

Timeline

Start

2020-09-29

Primary completion

2020-10-23

Completion

2020-10-23

Outcome

Outcome not reported

Stopped: “Amgen Decision”

Drugs

Indications